Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2023-10-03 00:00:00 ET · period of report 2023-09-27 · accession 0001787306-23-000113 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-10-03 | 2023-09-27 | ARQT | Edwards Larry Todd | Chief Commercial Off | A - Grant | $0.00 | +60.0K | 60.0K | New | $0 |
| D | 2023-10-03 | 2023-09-27 | ARQT | Edwards Larry Todd | Chief Commercial Off | A - Grant | $0.00 | +240.0K | 240.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-27 | A | A | 60,000 | $0.00 | 60,000 | D | — | — | (F1) The Restricted Stock Units ("RSUs") will vest as to 25% of the RSUs on each annual anniversary of October 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2023-09-27 | A | A | 240,000 | $0.00 | 240,000 | D | $5.58 · — to 2033-09-27 | 240,000 Common Stock | (F2) The option will vest and become exercisable as to 25% of the shares subject to the option on October 1, 2024, and the remaining options will vest at 2.0833% subject to the options on each monthly anniversary thereafter, subject to Reporting Person's continued service through the applicable vesting date. |